2.22

1.33% -0.03

Lexicon Pharmaceuticals Inc (LXRX)

Overview News Price History Option Chain Financials Why LXRX Down? Discussions Forecast Stock Split

Lexicon Pharmaceuticals Inc stock is traded at $2.22, with a volume of 2.30M. It is down -1.33% in the last 24 hours and up +18.09% over the past month. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Previous Close:

$2.25

Open:

$2.25

24h Volume:

2.30M

Relative Volume:

0.73

Market Cap:

$986.12M

Revenue:

$69.64M

Net Income/Loss:

$-26.09M

P/E Ratio:

-31.05

EPS:

-0.0715

Net Cash Flow:

$-38.80M

1W Performance:

-4.31%

1M Performance:

+18.09%

6M Performance:

+89.74%

1Y Performance:

+96.46%

1-Day Range:

$2.14

$2.25

1-Week Range:

$2.14

$2.435

52-Week Range:

$1.00

$2.68

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name

Lexicon Pharmaceuticals Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(281) 863-3000

Address

2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS

Employee

Twitter

@LexPharma

Next Earnings Date

2026-08-05

Latest SEC Filings

LXRX's Discussions on Twitter

Compare LXRX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXRX Lexicon Pharmaceuticals Inc	2.22	986.12M	69.64M	-26.09M	-38.80M	-0.0715
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jun-17-24	Initiated	H.C. Wainwright	Buy
Apr-30-24	Initiated	Leerink Partners	Outperform
Mar-07-23	Initiated	Jefferies	Hold
Aug-12-22	Initiated	Piper Sandler	Overweight
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy
Jul-29-19	Downgrade	Stifel	Buy → Hold
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Mar-01-17	Reiterated	H.C. Wainwright	Buy
Mar-01-17	Reiterated	Wedbush	Outperform
Oct-07-16	Initiated	H.C. Wainwright	Buy
Aug-05-16	Reiterated	Wedbush	Outperform
Aug-02-16	Initiated	Citigroup	Buy
Mar-02-16	Reiterated	Wedbush	Outperform
Nov-09-15	Reiterated	Wedbush	Outperform
Sep-28-15	Upgrade	Gabelli & Co	Sell → Hold
Sep-18-15	Downgrade	Gabelli & Co	Hold → Sell
Aug-10-15	Downgrade	JP Morgan	Overweight → Neutral

View All

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

Jul 10, 2026

What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders - simplywall.st

Jul 10, 2026

Jul 08, 2026

Lexicon Pharmaceuticals outlines its path in gastrointestinal disease. Drug pipeline and Nasdaq list - ad-hoc-news.de

Jul 08, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally - ChartMill

Jul 08, 2026

Jul 07, 2026

Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin - ad-hoc-news.de

Jul 07, 2026

Jul 06, 2026

LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill

Jul 06, 2026

Jul 05, 2026

Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com

Jul 05, 2026

Jul 03, 2026

Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion - Yahoo Finance

Jul 03, 2026

Jul 01, 2026

How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX) - simplywall.st

Jul 01, 2026

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Here's why you should add LXRX stock to your portfolio now - MSN

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 28, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

LXRX Surges As Traders Pounce On Strong Breakout - StocksToTrade

Jun 28, 2026

LXRX Jumps As Traders Focus On Breakout Momentum - timothysykes.com

Jun 28, 2026

Jun 27, 2026

LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders - StocksToTrade

Jun 27, 2026

LXRX Climbs As Bulls Press Multi-Day Breakout - timothysykes.com

Jun 27, 2026

Jun 26, 2026

Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com - Investing.com Nigeria

Jun 26, 2026

Lexicon Pharmaceuticals debuts HCM education booth at heart failure conference - Traders Union

Jun 23, 2026